help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weeke, J.
Right arrow Articles by Lundaek, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weeke, J.
Right arrow Articles by Lundaek, K.

Journal of Clinical Endocrinology & Metabolism, Vol 41, 168-171, Copyright © 1975 by Endocrine Society

ARTICLES

Inhibition by somatostatin of basal levels of serum thyrotropin (TSH) in normal men

J Weeke, AP Hansen and K Lundaek

To elucidate the effect of somatostatin on basal, unstimulated TSH secretion 6 young healthy nonobese men were studied with blood samples every 15 min from 2300 h to 0500 h. Somatostatin 1 mg was indused over a 2-h period from 0100 h. One of the subjects was also studied with half hourly blood samples throughout a 26-h period without receiving somatostatin. In all cases the high night levels of serum thyrotropin (TSH) were significantly suppressed by somatostatin. The fall of TSH continued throughout the two hour infusion period. Immediately upon termination of the infusion serum TSH increased rapidly to preinfusion values. The 26-h control study showed the typical diurnal pattern of serum TSH with low values in the daytime and high values at night. The serum triiodothyronine (T3) and thyroxine (T4) levels were not changed by somatostatin infusion. From these results we suggest that endogenous somatostatin may be of physiological importance in the regulation of the TSH secretion.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
D. M. Keenan, F. Roelfsema, N. Biermasz, and J. D. Veldhuis
Physiological control of pituitary hormone secretory-burst mass, frequency, and waveform: a statistical formulation and analysis
Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2003; 285(3): R664 - R673.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Caron, S. Arlot, C. Bauters, P. Chanson, J.-M. Kuhn, M. Pugeat, R. Marechaud, C. Teutsch, E. Vidal, and P. Sassano
Efficacy of the Long-Acting Octreotide Formulation (Octreotide-Lar) in Patients with Thyrotropin-Secreting Pituitary Adenomas
J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2849 - 2853.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. M. Kuhn, S. Arlot, H. Lefebvre, P. Caron, C. Cortet-Rudelli, F. Archambaud, P. Chanson, A. Tabarin, M. Goth, J. Blumberg, et al.
Evaluation of the Treatment of Thyrotropin-Secreting Pituitary Adenomas with a Slow Release Formulation of the Somatostatin Analog Lanreotide
J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1487 - 1491.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1975 by The Endocrine Society